77 related articles for article (PubMed ID: 9421938)
1. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
2. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.
Lin YH; Chen CL; Hou CP; Chang PL; Tsui KH
Acta Pharmacol Sin; 2011 Apr; 32(4):537-42. PubMed ID: 21399652
[TBL] [Abstract][Full Text] [Related]
3. Can Subepididymal Orchiectomy Re-emerge as the Treatment of Choice in Patients with Advanced Prostatic Carcinoma?
Agarwal M; Agrawal MS
Indian J Surg; 2015 Feb; 77(1):23-7. PubMed ID: 25829707
[TBL] [Abstract][Full Text] [Related]
4. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.
Francini E; Petrioli R; Rossi G; Laera L; Roviello G
Tumour Biol; 2014 Nov; 35(11):10601-7. PubMed ID: 25195134
[TBL] [Abstract][Full Text] [Related]
5. Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.
Grivas PD; Robins DM; Hussain M
Crit Rev Oncol Hematol; 2013 Jan; 85(1):82-93. PubMed ID: 22705096
[TBL] [Abstract][Full Text] [Related]
6. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
Yu EY; Gulati R; Telesca D; Jiang P; Tam S; Russell KJ; Nelson PS; Etzioni RD; Higano CS
J Clin Oncol; 2010 Jun; 28(16):2668-73. PubMed ID: 20421544
[TBL] [Abstract][Full Text] [Related]
7. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
8. The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer.
Kiper A; Yiğitbasi O; Imamoglu A; Tuygun C; Turan C
Int Urol Nephrol; 2006; 38(3-4):571-6. PubMed ID: 17171425
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
10. [Progress of endocrine therapy for prostate cancer and results].
Kanetake H
Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
[TBL] [Abstract][Full Text] [Related]
11. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Derde MP; Kaufman L
Acta Urol Belg; 1995 Sep; 63(3):1-9. PubMed ID: 7484516
[TBL] [Abstract][Full Text] [Related]
13. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
